Embryonic Stem Cell-Like Population in Dupuytren's Disease Expresses Components of the Renin-Angiotensin System

Overview

Journal Plast Reconstr Surg Glob Open

Specialty General Surgery

Date 2017 Aug 24

PMID 28831359

Citations 6

Authors

Nicholas On

Sabrina P Koh

Helen D Brasch

Jonathan C Dunne

James R Armstrong

Swee T Tan

Tinte Itinteang

Affiliations

Soon will be listed here.

Abstract

Methods: 3,3-Diaminobenzidine (DAB) and immunofluorescent immunohistochemical (IHC) staining for (pro)renin receptor (PRR), angiotensin-converting enzyme (ACE), angiotensin II receptor 1 (ATIIR1), and angiotensin II receptor 2 (ATIIR2) was performed on 4-μm thick formalin-fixed paraffin-embedded sections of DD cords and nodules from 6 patients. Western blotting (WB) and NanoString mRNA analysis were performed to confirm RAS protein expression and transcriptional activation, respectively.

Results: IHC staining demonstrated the expression of PRR, ACE, ATIIR1, and ATIIR2 on the ERG and CD34 endothelium of the micro vessels surrounding the DD cords and nodules. PRR was also expressed on the pericyte layer of these microvessels. WB confirmed protein expression of PRR, ACE, and ATIIR2 but not ATIIR1. NanoString analysis confirmed transcriptional activation of PRR, ACE, ATIIR1, but ATIIR2 was below detectable levels.

Conclusions: We demonstrated expression of PRR, ATIIR1, ATIIR2, and ACE on the embryonic stem cell-like cell population on the microvessels surrounding DD nodules and cords by IHC staining, although the expression of ATIIR1 was not confirmed by WB and that of ATIIR2 was below detectable levels on NanoString analysis. These findings suggest the embryonic stem cell-like cell population as a potential therapeutic target for DD, by using RAS modulators.

Citing Articles

Insights Into Vascular Anomalies, Cancer, and Fibroproliferative Conditions: The Role of Stem Cells and the Renin-Angiotensin System.

Kilmister E, Tan S Front Surg. 2022; 9:868187.

PMID: 35574555 PMC: 9091963. DOI: 10.3389/fsurg.2022.868187.

Stem Cells in Keloid Lesions: A Review.

Lim K, Itinteang T, Davis P, Tan S Plast Reconstr Surg Glob Open. 2019; 7(5):e2228.

PMID: 31333955 PMC: 6571348. DOI: 10.1097/GOX.0000000000002228.

Expression of Components of the Renin-Angiotensin System by the Putative Stem Cell Population Within WHO Grade I Meningioma.

Shivapathasundram G, Wickremesekera A, Brasch H, van Schaijik B, Marsh R, Tan S Front Surg. 2019; 6:23.

PMID: 31157231 PMC: 6532688. DOI: 10.3389/fsurg.2019.00023.

Assessment of palmar subcutaneous tissue vascularization in patients with Dupuytren's contracture.

Shchudlo N, Varsegova T, Stupina T, Dolganova T, Shchudlo M, Shihaleva N World J Orthop. 2018; 9(9):130-137.

PMID: 30254969 PMC: 6153130. DOI: 10.5312/wjo.v9.i9.130.

The Role of Stem Cells in Dupuytren's Disease: A Review.

Tan K, Withers A, Tan S, Itinteang T Plast Reconstr Surg Glob Open. 2018; 6(5):e1777.

PMID: 29922559 PMC: 5999435. DOI: 10.1097/GOX.0000000000001777.

References

van Beuge M, Ten Dam E, Werker P, Bank R . Wnt pathway in Dupuytren disease: connecting profibrotic signals. Transl Res. 2015; 166(6):762-771.e3. DOI: 10.1016/j.trsl.2015.09.006. View

Chen N, Srinivasan R, Shauver M, Chung K . A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture. Hand (N Y). 2012; 6(3):250-5. PMC: 3153627. DOI: 10.1007/s11552-011-9326-8. View

Viil J, Maasalu K, Maemets-Allas K, Tamming L, Lohmussaar K, Tooming M . Laminin-rich blood vessels display activated growth factor signaling and act as the proliferation centers in Dupuytren's contracture. Arthritis Res Ther. 2015; 17:144. PMC: 4475288. DOI: 10.1186/s13075-015-0661-y. View

Rosenkranz S . TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res. 2004; 63(3):423-32. DOI: 10.1016/j.cardiores.2004.04.030. View

Iannello S, Milazzo P, Bordonaro F, Belfiore F . Low-dose enalapril in the treatment of surgical cutaneous hypertrophic scar and keloid--two case reports and literature review. MedGenMed. 2007; 8(4):60. PMC: 1868346. View

Rayan G . Dupuytren disease: Anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007; 89(1):189-98. DOI: 10.2106/00004623-200701000-00026. View

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

Rayan G, Parizi M, Tomasek J . Pharmacologic regulation of Dupuytren's fibroblast contraction in vitro. J Hand Surg Am. 1996; 21(6):1065-70. DOI: 10.1016/S0363-5023(96)80317-0. View

Hindocha S, McGrouther D, Bayat A . Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (N Y). 2009; 4(3):256-69. PMC: 2724613. DOI: 10.1007/s11552-008-9160-9. View

10.

Quante M, Tu S, Tomita H, Gonda T, Wang S, Takashi S . Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011; 19(2):257-72. PMC: 3060401. DOI: 10.1016/j.ccr.2011.01.020. View

11.

Koh S, On N, Brasch H, Chibnall A, Armstrong J, Davis P . Embryonic Stem Cell-like Population in Dupuytren's Disease. Plast Reconstr Surg Glob Open. 2016; 4(11):e1064. PMC: 5142473. DOI: 10.1097/GOX.0000000000001064. View

12.

Armstrong J, Hurren J, Logan A . Dermofasciectomy in the management of Dupuytren's disease. J Bone Joint Surg Br. 2000; 82(1):90-4. DOI: 10.1302/0301-620x.82b1.9808. View

13.

Meek R, McLellan S, Reilly J, Crossan J . The effect of steroids on Dupuytren's disease: role of programmed cell death. J Hand Surg Br. 2002; 27(3):270-3. DOI: 10.1054/jhsb.2001.0742. View

14.

Hindocha S, Iqbal S, Farhatullah S, Paus R, Bayat A . Characterization of stem cells in Dupuytren's disease. Br J Surg. 2010; 98(2):308-15. DOI: 10.1002/bjs.7307. View

15.

Musumeci M, Vadala G, Russo F, Pelacchi F, Lanotte A, Denaro V . Dupuytren's disease therapy: targeting the vicious cycle of myofibroblasts?. Expert Opin Ther Targets. 2015; 19(12):1677-87. DOI: 10.1517/14728222.2015.1068758. View

16.

Bayat A, McGrouther D . Management of Dupuytren's disease--clear advice for an elusive condition. Ann R Coll Surg Engl. 2006; 88(1):3-8. PMC: 1963648. DOI: 10.1308/003588406X83104. View

17.

Iqbal S, Manning C, Syed F, Kolluru V, Hayton M, Watson S . Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy. Stem Cells Dev. 2011; 21(4):609-22. PMC: 3280606. DOI: 10.1089/scd.2011.0140. View

18.

Bataller R, Sancho-Bru P, Gines P, Lora J, Al-Garawi A, Sole M . Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003; 125(1):117-25. DOI: 10.1016/s0016-5085(03)00695-4. View

19.

Mezzano S, Ruiz-Ortega M, Egido J . Angiotensin II and renal fibrosis. Hypertension. 2001; 38(3 Pt 2):635-8. DOI: 10.1161/hy09t1.094234. View

20.

Nguyen G, Muller D . The biology of the (pro)renin receptor. J Am Soc Nephrol. 2009; 21(1):18-23. DOI: 10.1681/ASN.2009030300. View